e-ISSN 1309-2545      ISSN 1301-062X
TR    ENG
 

Download Current Issue.

Volume : 28 Issue : 2 Year : 2022

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login Copyright Transfer Form
Turkish Journal of Neurology Indexed By
  Therapentic Advances In Multiple Sclerosis [Turk J Neurol]
Turk J Neurol. 1998; 4(1): 34-40

Therapentic Advances In Multiple Sclerosis

Egemen İDİMAN
Dokuz Eylül Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı

Severak evidences suggest that immunopathological factors are critically involved in the pathogenesis of multiple sclerosis. Although significant progress has recently been obtained in the thraphy of multiple sclerosis, none of these therapies are entirely satisfactory. The three clinical trials demonstrated that IFN-ß Reference source not found. reduced the frequency and severity of exacerbations, slowed the accumulation of disability and supressed MRI activity and lesion accrual. Phase III multicentre copolimer-1 trial showed that glatiramer acetate had positive therapeutic effects in reducing relapse rate in relapsing-remitting multiple sclerosis (RRMS). Intravenous immunoglobulin was also shown to be beneficial in the treatment of RRMS.

Keywords: Current therapies in MS, Interfereon beta, glatiramer acetate, intravenous immunoglobulin


Egemen İDİMAN. Therapentic Advances In Multiple Sclerosis. Turk J Neurol. 1998; 4(1): 34-40

Corresponding Author: Egemen İDİMAN


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
© Copyright 2022 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale